Integrating the Neurobiology of Schizophrenia /

• Other Authors: Abi-Dargham, Anissa (Editor), Guillin, Olivier (Editor)
• Format: eBook
• Language: English
• Published: Amsterdam ; Boston : Elsevier, 2007.
• Series: International review of neurobiology ; v. 78.
• Subjects: Schizophrenia > Physiological aspects.; Schizophrenia > Chemotherapy.; PSYCHOLOGY > Psychopathology > Schizophrenia.; Electronic books.

 A thorough overview of all neurotransmitters involved in schizophrenia. 

 Cover -- Copyright Page -- Contents -- Contributors -- Preface -- References -- Chapter 1: Neurobiology of Dopamine in Schizophrenia -- I. Introduction -- II. Dopaminergic System in the Brain -- A. Dopaminergic Projections -- B. Dopaminergic Receptors -- III. Evidence Supporting Alterations of DA Systems in Schizophrenia -- A. Pharmacological Evidence -- B. Postmortem Studies -- C. Imaging Studies -- IV. Conclusions -- References -- Chapter 2: The Dopamine System and the Pathophysiology of Schizophrenia: A Basic Science Perspective -- I. Introduction -- II. Neuroanatomy of DA Systems -- III. DA Neuron Activity and Release -- IV. Cellular Actions of DA -- V. Roles of DA on Cognitive and Affective Functions -- VI. Development and Maturation of the DA System -- VII. DA Deficits in Schizophrenia -- VIII. Conclusions -- References -- Chapter 3: Glutamate and Schizophrenia: Phencyclidine, N-Methyl-D-Aspartate Receptors, and Dopamine-Glutamate Interactions -- I. Introduction -- II. Glutamatergic Physiology -- A. Glutamate-Dopamine Comparisons -- B. Glutamate Receptors -- C. NMDA Receptors -- D. AMPA/Kainate Receptors -- E. Metabotropic Receptors -- III. Glutamatergic Models of Schizophrenia -- A. Symptom Patterns Following NMDA Antagonist Administration -- B. Cognitive Deficits Following NMDA Antagonist Treatment -- C. In Vivo Findings in Schizophrenia Based on Dopamine Receptor Occupancy -- D. Postmortem Findings -- IV. Clinical Studies with NMDA Agonists -- A. NMDA Receptor Glycine-Site Agonists -- B. Glycine Transport Inhibitors -- C. Other Ionotropic Targets -- D. Metabotropic Receptors -- E. Group I Receptors -- F. Group II Metabotropic Agonists -- V. Potential Causes of Glutamatergic Dysfunction in Schizophrenia -- A. Dopamine-Glutamate Interactions -- B. Linkage-Association Studies in Schizophrenia -- C. Environmental and Neurochemical Factors -- VI. Future Research and Treatment Implications -- Acknowledgments -- References -- Chapter 4: Deciphering the Disease Process of Schizophrenia: the. Contribution of Cortical Gaba Neurons -- I. Working Memory Impairments: A Core Feature of Schizophrenia -- II. Working Memory Impairments and Altered GABA Neurotransmission in the DLPFC -- III. Potential Pathogenetic Mechanisms for Cell Type-Specific Alterations in GABA Neurons -- A. Reduced Excitatory Drive via NMDA Receptors -- B. Reduced Neurotrophin Signaling -- IV. Connecting Alterations in PV-Positive Neurons to Working Memory Impairments: Decreased Gamma Band Synchrony in Schizophrenia -- V. Treatment Implications -- Acknowledgments -- References -- Chapter 5: Alterations of Serotonin Transmission in Schizophrenia -- I. Introduction -- II. Alteration of 5-HT Receptors in Schizophrenia -- A. 5-HT Transporters -- B. 5-HT1A Receptors -- C. 5-HT2 Receptors -- D. Other Receptors -- III. Pharmacological Manipulation of 5-HT Transmission in Schizophrenia -- A. 5-HT Precursors -- B. 5-HT Depleting Agents -- C. 5-HT2A Agonism: LSD and "Model&#3.